Motifene Dual (Diclofenac Sodium)

Diclofenac Sodium, the active ingredient in Motifene Dual, is a nonsteroidal anti-inflammatory drug (NSAID) presented as a tablet for oral use. It relieves mild to moderate pain and inflammation in conditions such as osteoarthritis, rheumatoid arthritis, and musculoskeletal injuries.

GNH USA supplies Motifene Dual as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Diclofenac Sodium acts on inflammatory pathways to reduce pain and swelling in several musculoskeletal disorders. - Osteoarthritis: alleviates joint pain and improves functional mobility. - Rheumatoid arthritis: decreases synovial inflammation and joint tenderness. - Musculoskeletal pain: provides analgesic relief for sprains, strains, and low‑back discomfort.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Gastrointestinal discomfort or dyspepsia - Nausea or vomiting - Headache - Dizziness - Skin rash or pruritus - Elevated liver enzymes

Serious or Rare Side Effects: - Gastrointestinal ulceration or bleeding - Hepatic injury or jaundice - Acute renal failure or reduced kidney function - Severe cutaneous reactions (e.g., Stevens‑Johnson syndrome) - Cardiovascular events such as myocardial infarction - Anaphylactic or severe allergic reactions

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for potential complications. - Renal function: assess baseline creatinine and adjust use in renal impairment. - Hepatic health: monitor liver enzymes, especially with prolonged treatment. - Gastrointestinal risk: avoid in patients with active peptic ulcer disease or a history of GI bleeding. - Concomitant anticoagulants: use the lowest effective dose and monitor coagulation parameters. - Cardiovascular caution: consider risk in patients with established heart disease. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Diclofenac Sodium can alter the pharmacokinetics or pharmacodynamics of several co‑administered medicines.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Lithium: elevated serum lithium levels. - Methotrexate: reduced clearance leading to toxicity. - SSRIs (e.g., sertraline): heightened gastrointestinal bleeding. - ACE inhibitors (e.g., enalapril): possible reduction in renal function.

Moderate Interactions (Monitor Closely): - Other NSAIDs or COX‑2 inhibitors: additive gastrointestinal toxicity. - Diuretics (e.g., furosemide): potential renal impairment. - Beta‑blockers: may blunt antihypertensive effect. - Corticosteroids: increased risk of ulceration. - Cyclosporine: enhanced nephrotoxicity.